SCHEMBL4680796

SCHEMBL4680796

CN1CCCC[C@H]1CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2421142 1.00
SCHEMBL25262256 1.00 CYP1A2 (0.55)
SCHEMBL283488 1.00
Hydrochloric Acid SCHEMBL11468862 0.98 CYP1A2 (0.53)
SCHEMBL7279980 0.98 CYP1A2 (0.59)
SCHEMBL84792 0.93
SCHEMBL1086946 0.93
SCHEMBL26011205 0.93
SCHEMBL30917693 0.93
SCHEMBL178545 0.93

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079853-A N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases 2026-05-26 CN disclosed
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 US disclosed
US-20250206745-A1 PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES NODTHERA LTD (GB) 2025-06-26 US disclosed
EP-4551566-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS Les Laboratoires Servier (FR) 2025-05-14 EP disclosed
US-20250145639-A1 MUTANT KRAS MODULATORS AND USES THEREOF NEWAVE PHARMACEUTICAL INC (US) 2025-05-08 US disclosed
WO-2025087431-A1 PAN-KRAS INHIBITOR AND USE THEREOF IN MEDICINES 贝达药业股份有限公司 2025-05-01 WO disclosed
US-12139499-B2 Heteroaryl compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2024-11-12 US disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 CN disclosed
EP-4349828-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Yingli Pharmaceutical Co. Ltd. (CN) 2024-04-10 EP disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 US disclosed
EP-1333834-B1 ANTIINFLAMMATION AGENTS AMGEN INC (US) 2008-04-23 EP disclosed
US-20070135464-A1 Antiinflammation agents AMGEN, INC. 2007-06-14 US disclosed
US-20070135464-A1 Antiinflammation agents AMGEN, INC. 2007-06-14 US disclosed
US-20070135464-A1 Antiinflammation agents AMGEN, INC. 2007-06-14 US disclosed
US-7186841-B2 (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders AMGEN INC. (US) 2007-03-06 US disclosed
US-7186841-B2 (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders AMGEN INC. (US) 2007-03-06 US disclosed
US-7186841-B2 (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders AMGEN INC. (US) 2007-03-06 US disclosed
US-20050043330-A1 Antiinflammation agents AMGEN INC. (US) 2005-02-24 US disclosed
US-6846834-B2 Compounds contain fused carbocyclic or heterocyclic rings; modulate expression and/or function of proteins involved in inflammation, metabolism and cell proliferation AMGEN INC. (US) 2005-01-25 US disclosed
WO-2005002577-A1 DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA F. HOFFMANN-LA ROCHE AG (CH) 2005-01-13 WO disclosed